Biological treatments in giant cell arteritis & Takayasu arteritis.
Identifieur interne : 001470 ( Main/Exploration ); précédent : 001469; suivant : 001471Biological treatments in giant cell arteritis & Takayasu arteritis.
Auteurs : Maxime Samson [Espagne] ; Georgina Espígol-Frigolé [Espagne] ; Nekane Terrades-García [Espagne] ; Sergio Prieto-González [Espagne] ; Marc Corbera-Bellalta [Espagne] ; Roser Alba-Rovira [Espagne] ; José Hernández-Rodríguez [Espagne] ; Sylvain Audia [France] ; Bernard Bonnotte [France] ; Maria C. Cid [Espagne]Source :
- European journal of internal medicine [ 1879-0828 ] ; 2018.
Descripteurs français
- KwdFr :
- MESH :
- antagonistes et inhibiteurs : Facteur de nécrose tumorale alpha.
- usage thérapeutique : Anticorps monoclonaux humanisés, Glucocorticoïdes.
- Artérite à cellules géantes, Biothérapie, Essais contrôlés randomisés comme sujet, Humains, Maladie de Takayashu.
English descriptors
- KwdEn :
- MESH :
- chemical , antagonists & inhibitors : Tumor Necrosis Factor-alpha.
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized, Glucocorticoids.
- therapy : Giant Cell Arteritis, Takayasu Arteritis.
- Biological Therapy, Humans, Randomized Controlled Trials as Topic.
Abstract
Giant cell arteritis (GCA) and Takayasu arteritis (TAK) are the two main large vessel vasculitides. They share some similarities regarding their clinical, radiological and histological presentations but some pathogenic processes in GCA and TAK are activated differently, thus explaining their different sensitivity to biological therapies. The treatment of GCA and TAK essentially relies on glucocorticoids. However, thanks to major progress in our understanding of their pathogenesis, the role of biological therapies in the treatment of these two vasculitides is expanding, especially in relapsing or refractory diseases. In this review, the efficacy, the safety and the limits of the main biological therapies ever tested in GCA and TAK are discussed. Briefly, anti TNF-α agents appear to be effective in treating TAK but not GCA. Recent randomized placebo-controlled trials have reported on the efficacy and safety of abatacept and mostly tocilizumab in inducing and maintaining remission of GCA. Abatacept was not effective in TAK and robust data are still lacking to draw any conclusions concerning the use of tocilizumab in TAK. Furthermore, ustekinumab appears promising in relapsing/refractory GCA whereas rituximab has been reported to be effective in only a few cases of refractory TAK patients. If a biological therapy is indicated, and in light of the data discussed in this review, the first choice would be tocilizumab in GCA and anti-TNF-α agents (mainly infliximab) in TAK.
DOI: 10.1016/j.ejim.2017.11.003
PubMed: 29146018
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000952
- to stream PubMed, to step Curation: 000952
- to stream PubMed, to step Checkpoint: 000900
- to stream Ncbi, to step Merge: 001822
- to stream Ncbi, to step Curation: 001822
- to stream Ncbi, to step Checkpoint: 001822
- to stream Main, to step Merge: 001469
- to stream Main, to step Curation: 001470
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Biological treatments in giant cell arteritis & Takayasu arteritis.</title><author><name sortKey="Samson, Maxime" sort="Samson, Maxime" uniqKey="Samson M" first="Maxime" last="Samson">Maxime Samson</name><affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine and Clinical Immunology, François Mitterrand Hospital, Dijon University Hospital, Dijon, France; INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, Dijon, France; Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. Electronic address: maxime.samson@chu-dijon.fr.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Internal Medicine and Clinical Immunology, François Mitterrand Hospital, Dijon University Hospital, Dijon, France; INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, Dijon, France; Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Espigol Frigole, Georgina" sort="Espigol Frigole, Georgina" uniqKey="Espigol Frigole G" first="Georgina" last="Espígol-Frigolé">Georgina Espígol-Frigolé</name><affiliation wicri:level="3"><nlm:affiliation>Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Terrades Garcia, Nekane" sort="Terrades Garcia, Nekane" uniqKey="Terrades Garcia N" first="Nekane" last="Terrades-García">Nekane Terrades-García</name><affiliation wicri:level="3"><nlm:affiliation>Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Prieto Gonzalez, Sergio" sort="Prieto Gonzalez, Sergio" uniqKey="Prieto Gonzalez S" first="Sergio" last="Prieto-González">Sergio Prieto-González</name><affiliation wicri:level="3"><nlm:affiliation>Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Corbera Bellalta, Marc" sort="Corbera Bellalta, Marc" uniqKey="Corbera Bellalta M" first="Marc" last="Corbera-Bellalta">Marc Corbera-Bellalta</name><affiliation wicri:level="3"><nlm:affiliation>Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Alba Rovira, Roser" sort="Alba Rovira, Roser" uniqKey="Alba Rovira R" first="Roser" last="Alba-Rovira">Roser Alba-Rovira</name><affiliation wicri:level="3"><nlm:affiliation>Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Hernandez Rodriguez, Jose" sort="Hernandez Rodriguez, Jose" uniqKey="Hernandez Rodriguez J" first="José" last="Hernández-Rodríguez">José Hernández-Rodríguez</name><affiliation wicri:level="3"><nlm:affiliation>Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Audia, Sylvain" sort="Audia, Sylvain" uniqKey="Audia S" first="Sylvain" last="Audia">Sylvain Audia</name><affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine and Clinical Immunology, François Mitterrand Hospital, Dijon University Hospital, Dijon, France; INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, Dijon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Internal Medicine and Clinical Immunology, François Mitterrand Hospital, Dijon University Hospital, Dijon, France; INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, Dijon</wicri:regionArea><placeName><region type="region">Bourgogne-Franche-Comté</region><region type="old region">Bourgogne</region><settlement type="city">Dijon</settlement></placeName></affiliation></author><author><name sortKey="Bonnotte, Bernard" sort="Bonnotte, Bernard" uniqKey="Bonnotte B" first="Bernard" last="Bonnotte">Bernard Bonnotte</name><affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine and Clinical Immunology, François Mitterrand Hospital, Dijon University Hospital, Dijon, France; INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, Dijon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Internal Medicine and Clinical Immunology, François Mitterrand Hospital, Dijon University Hospital, Dijon, France; INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, Dijon</wicri:regionArea><placeName><region type="region">Bourgogne-Franche-Comté</region><region type="old region">Bourgogne</region><settlement type="city">Dijon</settlement></placeName></affiliation></author><author><name sortKey="Cid, Maria C" sort="Cid, Maria C" uniqKey="Cid M" first="Maria C" last="Cid">Maria C. Cid</name><affiliation wicri:level="3"><nlm:affiliation>Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:29146018</idno><idno type="pmid">29146018</idno><idno type="doi">10.1016/j.ejim.2017.11.003</idno><idno type="wicri:Area/PubMed/Corpus">000952</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000952</idno><idno type="wicri:Area/PubMed/Curation">000952</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000952</idno><idno type="wicri:Area/PubMed/Checkpoint">000900</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000900</idno><idno type="wicri:Area/Ncbi/Merge">001822</idno><idno type="wicri:Area/Ncbi/Curation">001822</idno><idno type="wicri:Area/Ncbi/Checkpoint">001822</idno><idno type="wicri:Area/Main/Merge">001469</idno><idno type="wicri:Area/Main/Curation">001470</idno><idno type="wicri:Area/Main/Exploration">001470</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Biological treatments in giant cell arteritis & Takayasu arteritis.</title><author><name sortKey="Samson, Maxime" sort="Samson, Maxime" uniqKey="Samson M" first="Maxime" last="Samson">Maxime Samson</name><affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine and Clinical Immunology, François Mitterrand Hospital, Dijon University Hospital, Dijon, France; INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, Dijon, France; Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. Electronic address: maxime.samson@chu-dijon.fr.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Internal Medicine and Clinical Immunology, François Mitterrand Hospital, Dijon University Hospital, Dijon, France; INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, Dijon, France; Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Espigol Frigole, Georgina" sort="Espigol Frigole, Georgina" uniqKey="Espigol Frigole G" first="Georgina" last="Espígol-Frigolé">Georgina Espígol-Frigolé</name><affiliation wicri:level="3"><nlm:affiliation>Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Terrades Garcia, Nekane" sort="Terrades Garcia, Nekane" uniqKey="Terrades Garcia N" first="Nekane" last="Terrades-García">Nekane Terrades-García</name><affiliation wicri:level="3"><nlm:affiliation>Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Prieto Gonzalez, Sergio" sort="Prieto Gonzalez, Sergio" uniqKey="Prieto Gonzalez S" first="Sergio" last="Prieto-González">Sergio Prieto-González</name><affiliation wicri:level="3"><nlm:affiliation>Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Corbera Bellalta, Marc" sort="Corbera Bellalta, Marc" uniqKey="Corbera Bellalta M" first="Marc" last="Corbera-Bellalta">Marc Corbera-Bellalta</name><affiliation wicri:level="3"><nlm:affiliation>Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Alba Rovira, Roser" sort="Alba Rovira, Roser" uniqKey="Alba Rovira R" first="Roser" last="Alba-Rovira">Roser Alba-Rovira</name><affiliation wicri:level="3"><nlm:affiliation>Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Hernandez Rodriguez, Jose" sort="Hernandez Rodriguez, Jose" uniqKey="Hernandez Rodriguez J" first="José" last="Hernández-Rodríguez">José Hernández-Rodríguez</name><affiliation wicri:level="3"><nlm:affiliation>Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Audia, Sylvain" sort="Audia, Sylvain" uniqKey="Audia S" first="Sylvain" last="Audia">Sylvain Audia</name><affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine and Clinical Immunology, François Mitterrand Hospital, Dijon University Hospital, Dijon, France; INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, Dijon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Internal Medicine and Clinical Immunology, François Mitterrand Hospital, Dijon University Hospital, Dijon, France; INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, Dijon</wicri:regionArea><placeName><region type="region">Bourgogne-Franche-Comté</region><region type="old region">Bourgogne</region><settlement type="city">Dijon</settlement></placeName></affiliation></author><author><name sortKey="Bonnotte, Bernard" sort="Bonnotte, Bernard" uniqKey="Bonnotte B" first="Bernard" last="Bonnotte">Bernard Bonnotte</name><affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine and Clinical Immunology, François Mitterrand Hospital, Dijon University Hospital, Dijon, France; INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, Dijon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Internal Medicine and Clinical Immunology, François Mitterrand Hospital, Dijon University Hospital, Dijon, France; INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, Dijon</wicri:regionArea><placeName><region type="region">Bourgogne-Franche-Comté</region><region type="old region">Bourgogne</region><settlement type="city">Dijon</settlement></placeName></affiliation></author><author><name sortKey="Cid, Maria C" sort="Cid, Maria C" uniqKey="Cid M" first="Maria C" last="Cid">Maria C. Cid</name><affiliation wicri:level="3"><nlm:affiliation>Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author></analytic><series><title level="j">European journal of internal medicine</title><idno type="eISSN">1879-0828</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Biological Therapy</term><term>Giant Cell Arteritis (therapy)</term><term>Glucocorticoids (therapeutic use)</term><term>Humans</term><term>Randomized Controlled Trials as Topic</term><term>Takayasu Arteritis (therapy)</term><term>Tumor Necrosis Factor-alpha (antagonists & inhibitors)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Artérite à cellules géantes ()</term><term>Biothérapie</term><term>Essais contrôlés randomisés comme sujet</term><term>Facteur de nécrose tumorale alpha (antagonistes et inhibiteurs)</term><term>Glucocorticoïdes (usage thérapeutique)</term><term>Humains</term><term>Maladie de Takayashu ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Tumor Necrosis Factor-alpha</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Glucocorticoids</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Facteur de nécrose tumorale alpha</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Giant Cell Arteritis</term><term>Takayasu Arteritis</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Glucocorticoïdes</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Biological Therapy</term><term>Humans</term><term>Randomized Controlled Trials as Topic</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Artérite à cellules géantes</term><term>Biothérapie</term><term>Essais contrôlés randomisés comme sujet</term><term>Humains</term><term>Maladie de Takayashu</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Giant cell arteritis (GCA) and Takayasu arteritis (TAK) are the two main large vessel vasculitides. They share some similarities regarding their clinical, radiological and histological presentations but some pathogenic processes in GCA and TAK are activated differently, thus explaining their different sensitivity to biological therapies. The treatment of GCA and TAK essentially relies on glucocorticoids. However, thanks to major progress in our understanding of their pathogenesis, the role of biological therapies in the treatment of these two vasculitides is expanding, especially in relapsing or refractory diseases. In this review, the efficacy, the safety and the limits of the main biological therapies ever tested in GCA and TAK are discussed. Briefly, anti TNF-α agents appear to be effective in treating TAK but not GCA. Recent randomized placebo-controlled trials have reported on the efficacy and safety of abatacept and mostly tocilizumab in inducing and maintaining remission of GCA. Abatacept was not effective in TAK and robust data are still lacking to draw any conclusions concerning the use of tocilizumab in TAK. Furthermore, ustekinumab appears promising in relapsing/refractory GCA whereas rituximab has been reported to be effective in only a few cases of refractory TAK patients. If a biological therapy is indicated, and in light of the data discussed in this review, the first choice would be tocilizumab in GCA and anti-TNF-α agents (mainly infliximab) in TAK.</div></front></TEI><affiliations><list><country><li>Espagne</li><li>France</li></country><region><li>Bourgogne</li><li>Bourgogne-Franche-Comté</li><li>Catalogne</li></region><settlement><li>Barcelone</li><li>Dijon</li></settlement></list><tree><country name="Espagne"><region name="Catalogne"><name sortKey="Samson, Maxime" sort="Samson, Maxime" uniqKey="Samson M" first="Maxime" last="Samson">Maxime Samson</name></region><name sortKey="Alba Rovira, Roser" sort="Alba Rovira, Roser" uniqKey="Alba Rovira R" first="Roser" last="Alba-Rovira">Roser Alba-Rovira</name><name sortKey="Cid, Maria C" sort="Cid, Maria C" uniqKey="Cid M" first="Maria C" last="Cid">Maria C. Cid</name><name sortKey="Corbera Bellalta, Marc" sort="Corbera Bellalta, Marc" uniqKey="Corbera Bellalta M" first="Marc" last="Corbera-Bellalta">Marc Corbera-Bellalta</name><name sortKey="Espigol Frigole, Georgina" sort="Espigol Frigole, Georgina" uniqKey="Espigol Frigole G" first="Georgina" last="Espígol-Frigolé">Georgina Espígol-Frigolé</name><name sortKey="Hernandez Rodriguez, Jose" sort="Hernandez Rodriguez, Jose" uniqKey="Hernandez Rodriguez J" first="José" last="Hernández-Rodríguez">José Hernández-Rodríguez</name><name sortKey="Prieto Gonzalez, Sergio" sort="Prieto Gonzalez, Sergio" uniqKey="Prieto Gonzalez S" first="Sergio" last="Prieto-González">Sergio Prieto-González</name><name sortKey="Terrades Garcia, Nekane" sort="Terrades Garcia, Nekane" uniqKey="Terrades Garcia N" first="Nekane" last="Terrades-García">Nekane Terrades-García</name></country><country name="France"><region name="Bourgogne-Franche-Comté"><name sortKey="Audia, Sylvain" sort="Audia, Sylvain" uniqKey="Audia S" first="Sylvain" last="Audia">Sylvain Audia</name></region><name sortKey="Bonnotte, Bernard" sort="Bonnotte, Bernard" uniqKey="Bonnotte B" first="Bernard" last="Bonnotte">Bernard Bonnotte</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001470 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001470 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:29146018
|texte= Biological treatments in giant cell arteritis & Takayasu arteritis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:29146018" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |